{"id":"W3165241302","doi":"10.1016/s1470-2045(21)00151-0","title":"Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":373,"is_retracted":false,"has_abstract":false,"ca_institutions":"Roche (Canada)","funders":"Genentech; F. Hoffmann-La Roche","keywords":"Medicine; Sorafenib; Bevacizumab; Atezolizumab; Internal medicine; Oncology; Hepatocellular carcinoma; Quality of life (healthcare); Response Evaluation Criteria in Solid Tumors; Clinical trial; Progression-free survival; Performance status; Cancer; Clinical endpoint; Phases of clinical research; Surgery; Chemotherapy; Pembrolizumab; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006697583,0.0005045771,0.001924551,0.000148321,0.0002379541,0.0001107486,0.0004487748,0.0002572526,0.000345445],"category_scores_gemma":[0.0001964001,0.0002993363,0.00009320449,0.0006279012,0.0002074271,0.0002283157,0.0002452405,0.0005301072,0.0000272463],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006774478,"about_ca_system_score_gemma":0.001711356,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005230851,"about_ca_topic_score_gemma":0.0005911901,"domain_scores_codex":[0.99595,0.0009373649,0.0007636099,0.0008110915,0.0006409114,0.0008969601],"domain_scores_gemma":[0.9972141,0.0004290617,0.0004141251,0.001270662,0.000365201,0.0003068509],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5884247,0.004032014,0.3983309,0.00003552017,0.0005832186,0.003652835,0.0006168416,0.000003126167,0.00008200949,0.00006157302,0.000203584,0.003973698],"study_design_scores_gemma":[0.940531,0.03429028,0.01770782,0.00006726325,0.0009985297,0.00009794001,0.0002754611,0.0009671217,0.001560237,0.00003603178,0.003051104,0.0004172792],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9887674,0.000322155,0.00001857796,0.001406646,0.0003970134,0.005677155,0.00004934317,0.0000832775,0.003278427],"genre_scores_gemma":[0.9961599,0.00003292434,0.000849097,0.0005137356,0.0002120583,0.0008168048,0.0009632483,0.00008471059,0.0003675857],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3806231,"threshold_uncertainty_score":0.9999459,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1298463038578968,"score_gpt":0.3448993800596667,"score_spread":0.2150530762017699,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}